BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 10, 2025
Home » Authors » Peter Winter

Peter Winter

Articles

ARTICLES

Financial chart, downward arrow
Health care equities hit hard

Panic selling craters the market despite fed stimulus

March 16, 2020
By Peter Winter
The circuit breakers activated almost immediately when the markets opened this morning as the Dow plummeted, with investors moving into cash and away from equities. Clearly, they were not impressed with the Federal Reserve’s decision to slash its benchmark interest rate to nearly 0% to help combat the economic fallout from the coronavirus outbreak.
Read More

Week in review for March 9-13, 2020: Biopharma equities caught in vortex of oil crash and coronavirus fears

March 16, 2020
By Peter Winter
A quick look back at top stories.
Read More
R&D money

Biopharmas increase their R&D spending in 2019, analysis finds

March 10, 2020
By Peter Winter
According to an analysis conducted by BioWorld of the fourth-quarter and year-end 2019 financial reports filed by the top 100 public biopharmaceutical companies ranked by market cap, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the year increased 35% compared to the same period in 2018.
Read More
Dollar sign, downward arrow

Biopharma equities caught in vortex of oil crash and coronavirus fears

March 9, 2020
By Peter Winter
The financial markets were delivered a one-two punch March 9 – a plunge in oil prices along with fears that the coronavirus is continuing to spread unabated. As a result, the Dow Jones Industrial Average cratered 1,500 points in early trading after a brief halt with market circuit breakers kicking in. Biopharma equities did not escape the carnage, with the BioWorld Biopharmaceutical index trading down about 4% by market close, with the Dow closing down 7.8%.
Read More

Week in review for March 2-6, 2020: Financial markets in freefall

March 9, 2020
By Peter Winter
A quick look back at top stories.
Read More
COVID-19 market impact illustration: coronavirus, currency symbols, line graph

Global spread of coronavirus puts financial markets into a tailspin

March 3, 2020
By Peter Winter
Concerns about the escalating global spread of COVID-19 panicked the markets big time at the close of the month. With investors rushing to the sidelines, it only took five days for the Dow Jones Industrial Average to drop more than 10% from its all-time high, getting close to the 30,000 mark.
Read More

Week in review for Feb. 24-28, 2020: Two migraine therapies approved

March 2, 2020
By Peter Winter
A quick look back at top stories, including: 1st Biotherapeutics, Acacia, Apeiron, Ascletis, Axovant, Bicycle, Biogen, Biohaven, Boehringer Ingelheim, Cocrystal, Curis, Glaxosmithkline, H. Lundbeck, Makscientific, MPM, NGM, Oramed, Pvp, Redhill, Roche, Sangamo, Shenzhen Xtalpi, Sichuan Clover, Steba, Takeda, Tetra, Tonix, Trutino, Twoxar, Vir, Wuxi.
Read More
Coronavirus test tube, microscope, gloved hand

Coronavirus outbreak brings focus on companies developing potential therapies

Feb. 25, 2020
By Peter Winter
The public attention that COVID-19 has received has spilled over to antibiotics companies, and the BioWorld Infectious Diseases index has grown 14% in value since the beginning of the year.
Read More

No pandemic, but pan-panic in the financial markets

Feb. 25, 2020
By Peter Winter
Although the World Health Organization (WHO) acknowledged COVID-19 is spreading, they say it has not yet reached pandemic disease status.
Read More
Financial chart, upward arrow

BioWorld Neurological Diseases index off to running start

Feb. 24, 2020
By Peter Winter
Investors continue to keep a close eye on the progress of companies involved in developing medicines targeting the central nervous system and, in the main, their reaction has been generally positive. The BioWorld Neurological Diseases index, a price-weighted index of public biopharmaceutical companies that are focused on developing therapies to treat neurological diseases, closed the year up over 16% and after, a dip in January, is now tracking up more than 12% by market close on Friday Feb. 21, well ahead of the general markets for the same period.
Read More
View All Articles by Peter Winter

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing